Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCSRT.L Regulatory News (CSRT)

  • There is currently no data for CSRT

Director/PDMR Shareholding

6 Feb 2020 16:31

RNS Number : 2564C
Consort Medical PLC
06 February 2020
 

 

Consort Medical plc ("Consort" or the "Company")

Notification and public disclosure by persons discharging managerial responsibilities ("PDMRs")

6 February 2020

Acquisition of entire issued and to be issued share capital of the Company by Recipharm Holdings Limited ("Recipharm"), a wholly-owned direct subsidiary of Recipharm AB, by way of a recommended cash offer (the "Offer") - exercise of share options held by PDMRs and disposal by PDMRs of shares under the Offer

Consort announces the following in relation to the PDMRs listed in the table below:

·; on 4 February 2020 (the "Takeover Date"), the PDMRs exercised share options (the "Options") under the Company's Share Plans (as detailed further in the table and the notifications below) which became exercisable in connection with the Offer, and the PDMRs became entitled to ordinary shares ("Shares") in the Company; and

·; on 5 February 2020, the PDMRs disposed of the Shares resulting from such exercise, and their SIP Shares (where relevant) (as detailed further in the table and the notifications below), to Recipharm under the terms of the Offer.

The Options were granted to the PDMRs under the Consort Performance Share Plan (the "PSP"), the Consort Deferred Bonus Plan (the "DBP") and the Consort Sharesave Plan (the "Sharesave Plan"). Certain of the PDMRs also hold Shares under the Consort Share Incentive Plan (the "SIP").

The Options were exercised by the PDMRs conditionally on the Takeover Date, and the PDMRs accepted the Offer in respect of the resulting Shares, under the terms of Recipharm's proposal made in accordance with Rule 15 of the Takeover Code. The PDMRs instructed the SIP Trustee to accept the Offer in respect of their SIP Shares, in accordance with the trust deed and rules of the SIP.

As set out in the document containing the Offer, the effect of the Offer on the interests the PDMRs does not differ from its effect on the interests of any other option holder or shareholder.

The exercise of the Options was satisfied by using all the Shares held in the Consort Medical plc Employee Share Ownership Trust, with the balance of Options satisfied by the issue of new Shares.

Following the acquisition by Recipharm of the Shares as detailed in this announcement, the PDMRs listed below hold no Shares in the Company.

Director/PDMR

DBP Shares

PSP Shares

Sharesave Shares

SIP Shares

Total Shares exercised and sold to Recipharm

 

Total Shares retained

Jonathan Glenn

50,875

160,599

193

9,065

220,732

0

Paul Hayes

19,120

127,108

387

467

147,082

0

Keyvan Djamarani

16,522

59,688

387

1,971

78,568

0

 

Enquiries: Andrew Jackson Company Secretary 01442 867920

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

 Jonathan Glenn

2

Reason for the notification

a)

 

Position/status

 

CEO

b)

 

Initial notification /Amendment

Initial

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

Consort Medical plc

b)

 

LEI

 

2138001TBP74FD66QT38

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary 10p shares

Identification code

ISIN: GB0000946276

b)

 

Nature of the transaction

 

1. Exercise of Options under the Deferred Bonus Plan and the Performance Share Plan

2. Sale of Shares resulting from exercise under the terms of the Offer

3. Exercise of Options under the Company's Sharesave Scheme

4. Sale of the Sharesave shares resulting from the exercise under the terms of the offer

5. Sale of the Share Incentive Plan shares under the terms of the offer

c)

 

Price(s) and volume(s)

 

 

 

 

 

Price(s)

Volume(s)

 

 

1. £0.00

211,474

 

 

2. £10.10

211,474

 

 

3. £7.74

193

 

 

4. £10.10

193

 

 

5. £10.10

9,065

 

 

 

 

 

d)

 

Aggregated information

n/a

- Aggregated volume

- Price

e)

 

Date of the transaction

 

Exercise of options: 4 February 2020

Sale of shares under offer: 5 February 2020

f)

 

Place of the transaction

 

Exercise of options: Off market

Sale of share under offer: London Stock Exchange

 

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

 Paul Hayes

2

Reason for the notification

a)

 

Position/status

 

CFO

b)

 

Initial notification /Amendment

Initial

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

Consort Medical plc

b)

 

LEI

 

2138001TBP74FD66QT38

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary 10p shares

Identification code

ISIN: GB0000946276

b)

 

Nature of the transaction

 

1. Exercise of Options under the Deferred Bonus Plan and the Performance Share Plan

2. Sale of Shares resulting from exercise under the terms of the Offer

3. Exercise of Options under the Company's Sharesave Scheme

4. Sale of the Sharesave shares resulting from the exercise under the terms of the offer

5. Sale of the Share Incentive Plan shares under the terms of the offer

c)

 

Price(s) and volume(s)

 

 

 

 

 

Price(s)

Volume(s)

 

 

1. £0.00

146,228

 

 

2. £10.10

146,228

 

 

3. £7.74

387

 

 

4. £10.10

387

 

 

5. £10.10

467

 

 

 

 

 

d)

 

Aggregated information

n/a

- Aggregated volume

- Price

e)

 

Date of the transaction

 

Exercise of options: 4 February 2020

Sale of shares under offer: 5 February 2020

f)

 

Place of the transaction

 

Exercise of options: Off market

Sale of share under offer: London Stock Exchange

 

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

 Keyvan Djamarani

2

Reason for the notification

a)

 

Position/status

 

Business President Bespak

b)

 

Initial notification /Amendment

Initial

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

Consort Medical plc

b)

 

LEI

 

2138001TBP74FD66QT38

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary 10p shares

Identification code

ISIN: GB0000946276

b)

 

Nature of the transaction

 

1. Exercise of Options under the Deferred Bonus Plan and the Performance Share Plan

2. Sale of Shares resulting from exercise under the terms of the Offer

3. Exercise of Options under the Company's Sharesave Scheme

4. Sale of the Sharesave shares resulting from the exercise under the terms of the offer

5. Sale of the Share Incentive Plan shares under the terms of the offer

c)

 

Price(s) and volume(s)

 

 

 

 

 

Price(s)

Volume(s)

 

 

1. £0.00

76,210

 

 

2. £10.10

76,210

 

 

3. £7.74

387

 

 

4. £10.10

387

 

 

5. £10.10

1,971

 

 

 

 

 

d)

 

Aggregated information

n/a

- Aggregated volume

- Price

e)

 

Date of the transaction

 

Exercise of options: 4 February 2020

Sale of shares under offer: 5 February 2020

f)

 

Place of the transaction

 

Exercise of options: Off market

Sale of share under offer: London Stock Exchange

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHQQLFBBLLLBBV
Date   Source Headline
15th Jun 20123:12 pmRNSDirector/PDMR Shareholding
14th Jun 20127:00 amRNSDirectorate
14th Jun 20127:00 amRNSPreliminary Results
6th Jun 20121:57 pmRNSBlocklisting Interim Review
1st May 201210:21 amRNSTotal Voting Rights
30th Apr 20127:00 amRNSFDA Approval Proprietary Integrated Dose Counter
20th Apr 201210:54 amRNSHolding(s) in Company
16th Apr 201211:37 amRNSBlocklisting Interim Review
28th Mar 20124:36 pmRNSHolding(s) in Company
22nd Mar 20129:58 amRNSAnnual Information Update
20th Mar 20124:25 pmRNSReplacement Interim Management Statement
20th Mar 20121:07 pmRNSInterim Management Statement
1st Mar 20129:00 amRNSTotal Voting Rights
17th Feb 201210:09 amRNSHolding(s) in Company
23rd Jan 20129:45 amRNSBlocklisting Interim Review
13th Dec 20112:25 pmRNSDirector/PDMR Shareholding
2nd Dec 20111:34 pmRNSBlocklisting Interim Review
1st Dec 20117:00 amRNSInterim results for the six months ended 31/10/11
19th Oct 20114:03 pmRNSHolding(s) in Company
17th Oct 20113:13 pmRNSHolding(s) in Company
14th Oct 20119:39 amRNSBlocklisting Interim Review
7th Oct 201112:13 pmRNSHolding(s) in Company
5th Oct 20114:47 pmRNSHolding(s) in Company
4th Oct 20117:00 amRNSSecond Nasal Drug Delivery Contract
27th Sep 20114:33 pmRNSHolding(s) in Company
26th Sep 20113:01 pmRNSHolding(s) in Company
2nd Sep 201110:21 amRNSTotal Voting Rights
1st Sep 20112:50 pmRNSResult of AGM
1st Sep 20112:47 pmRNSDirectorate Change
1st Sep 201112:40 pmRNSInterim Management Statement
1st Sep 20117:00 amRNSNasal Drug Delivery Contract
24th Aug 20114:35 pmRNSHolding(s) in Company
2nd Aug 20111:51 pmRNSDirector/PDMR Shareholding
2nd Aug 20111:47 pmRNSDirector/PDMR Shareholding
28th Jul 20119:14 amRNSAnnual Financial Report
20th Jul 20117:00 amRNSFurther re Investment in Atlas Genetics
30th Jun 20111:58 pmRNSTotal Voting Rights
24th Jun 20119:06 amRNSHolding(s) in Company
21st Jun 201112:33 pmRNSBlocklisting Interim Review
16th Jun 20117:00 amRNSPreliminary results for the year ended 30/04/11
2nd Jun 20117:00 amRNSBlocklisting Interim Review
10th May 20119:27 amRNSHolding(s) in Company
14th Apr 201110:20 amRNSBlocklisting Interim Review
4th Apr 201110:29 amRNSHolding(s) in Company
1st Apr 20111:51 pmRNSHolding(s) in Company
23rd Mar 20112:04 pmRNSAnnual Information Update
14th Mar 20117:00 amRNSInterim Management Statement
15th Feb 20114:14 pmRNSHolding(s) in Company
9th Feb 201111:15 amRNSDirectorate Change
7th Feb 20117:00 amRNSPartners with Atlas Genetics

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.